Xafiza Yusupova
Xafiza Yusupova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Guzal Abdullaeva
Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии
3 shared publications - Shaxlo Fayzullayeva
Respublika ixtisoslashtirilgan ilmiy-amaliy kardiologiya tibbiyot markazi
2 shared publications - A.D. Yuldasheva
Республиканского Специализированного Научно-практического Медицинского Центра Кардиологии
1 shared publication - Alisher Abdullaev
Center for Advanced Technologies, Tashkent 100174, Uzbekistan
1 shared publication - Gulnoz Xamidullayeva
Respublika ixtisoslashgan kardiologiya ilmiy-amaliy tibbiyot markazi
1 shared publication - Iroda Ibragimova
Республиканского Специализированного Научно-практического Медицинского Центра Кардиологии
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 169-178
Antigipertenziv preparatlarning kognitiv funksiyalarga ta’siri
According to the World Health Organization data, 1.13 billion people worldwide suffer from arterial hypertension, with only 21% under proper control. Dementia currently negatively affects the quality of life of 55 million people worldwide, with one new case recorded every 3.2 seconds. Analyzing the effects of antihypertensive medications on cognitive function and evaluating protective mechanisms against dementia development is currently considered one of the urgent issues. There is reliable evidence that the effects of antihypertensive medications on cognitive function are related not only to blood pressure reduction but also to independent neuroprotective mechanisms. Angiotensin receptor blockers reduce dementia risk by 12-26% compared to other antihypertensive medications. Calcium channel blockers demonstrate 17% greater neuroprotective effects compared to other drug classes. ARBs and calcium channel blockers possess the best neuroprotective properties and are considered preferable for cognitive function protection. These effects occur independently of blood pressure reduction mechanisms.
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 169-178
Open AccessAntigipertenziv preparatlarning kognitiv funksiyalarga ta’siri
According to the World Health Organization data, 1.13 billion people worldwide suffer from arterial hypertension, with only 21% under proper control. Dementia currently negatively affects the quality of life of 55 million people worldwide, with one new case recorded every 3.2 seconds. Analyzing the effects of antihypertensive medications on cognitive function and evaluating protective mechanisms against dementia development is currently considered one of the urgent issues. There is reliable evidence that the effects of antihypertensive medications on cognitive function are related not only to blood pressure reduction but also to independent neuroprotective mechanisms. Angiotensin receptor blockers reduce dementia risk by 12-26% compared to other antihypertensive medications. Calcium channel blockers demonstrate 17% greater neuroprotective effects compared to other drug classes. ARBs and calcium channel blockers possess the best neuroprotective properties and are considered preferable for cognitive function protection. These effects occur independently of blood pressure reduction mechanisms.
- Open Access
- 30 March 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (1) , 79-86
Polipill yurak qon-tomir kasalliklarini oldini olishda: samaradorlik va istiqbollari
Yurak-qon tomir kasalliklari (YuQTK) dunyo bo‘ylab kasallanish va o‘limning yetakchi sabablaridan biri hisoblanadi. Profilaktikaning samaradorligini oshirish maqsadida bir nechta dorivor moddalarni o‘z ichiga olgan polipill konsepsiyasi ilgari surilgan. Ushbu maqolada polipillning birlamchi va ikkilamchi profilaktikadagi o‘rni, uning afzalliklari va kamchiliklari tahlil qilinadi. Polipill birlamchi profilaktikada arterial gipertenziya, dislipidemiya va tromboz rivojlanishini oldini olish orqali YuQTK xavfini kamaytirishi mumkin. Ikkilamchi profilaktikada esa yurak xuruji va insult kabi holatlarning qayta yuzaga kelish ehtimolini pasaytirishga yordam beradi. Shuningdek, polipill dori qabul qilish tartibini yaxshilash va umumiy iqtisodiy xarajatlarni kamaytirish imkonini beradi.
- 30 March 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (1) , 79-86
Open AccessPolipill yurak qon-tomir kasalliklarini oldini olishda: samaradorlik va istiqbollari
Yurak-qon tomir kasalliklari (YuQTK) dunyo bo‘ylab kasallanish va o‘limning yetakchi sabablaridan biri hisoblanadi. Profilaktikaning samaradorligini oshirish maqsadida bir nechta dorivor moddalarni o‘z ichiga olgan polipill konsepsiyasi ilgari surilgan. Ushbu maqolada polipillning birlamchi va ikkilamchi profilaktikadagi o‘rni, uning afzalliklari va kamchiliklari tahlil qilinadi. Polipill birlamchi profilaktikada arterial gipertenziya, dislipidemiya va tromboz rivojlanishini oldini olish orqali YuQTK xavfini kamaytirishi mumkin. Ikkilamchi profilaktikada esa yurak xuruji va insult kabi holatlarning qayta yuzaga kelish ehtimolini pasaytirishga yordam beradi. Shuningdek, polipill dori qabul qilish tartibini yaxshilash va umumiy iqtisodiy xarajatlarni kamaytirish imkonini beradi.
- Open Access
- 23 January 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (2) , 101-110
Индивидуальный подход к терапии высокого риска: сравнительная оценка фиксированных и раздельных комбинаций антигипертензивных и гиполипидемических препаратов
Background. Uncontrolled arterial hypertension in patients at high and very high cardiovascular risk remains a significant issue in modern medicine. Optimizing antihypertensive therapy using fixed or separate combinations of drugs represents a promising approach to improving blood pressure control and reducing the risk of cardiovascular complications. Materials and methods. The study included 40 patients (men and women) with grade I–III hypertension according to the ESC/ESH classification (2018). The mean age was 51.52 ± 9.43 years, and the average disease duration was 8.52 ± 6.64 years. Patients were divided into two groups: one received a fixed combination (lisinopril/amlodipine/rosuvastatin), and the other received a separate combination (perindopril/amlodipine and rosuvastatin). Treatment lasted for 3 months. Effectiveness was assessed using 24-hour blood pressure monitoring, applanation tonometry, echocardiography, ultrasound examination of brachiocephalic arteries, and laboratory analyses (lipid profile, glucose level, uric acid, and creatinine). Results. Both therapy regimens demonstrated high antihypertensive, organoprotective, and hypolipidemic effectiveness. However, patients receiving the fixed combination showed a more significant reduction in systolic and diastolic blood pressure, improved lipid profile, and decreased nighttime blood pressure variability. No adverse effects on metabolic profiles were observed. Conclusion. The fixed combination of drugs demonstrated superiority over the separate combination regimen, providing better blood pressure control and lipid profile improvement. These findings highlight the importance of selecting optimal therapy regimens for high cardiovascular risk patients and confirm the efficacy of fixed combinations in this patient group.
- 23 January 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (2) , 101-110
Open AccessИндивидуальный подход к терапии высокого риска: сравнительная оценка фиксированных и раздельных комбинаций антигипертензивных и гиполипидемических препаратов
Background. Uncontrolled arterial hypertension in patients at high and very high cardiovascular risk remains a significant issue in modern medicine. Optimizing antihypertensive therapy using fixed or separate combinations of drugs represents a promising approach to improving blood pressure control and reducing the risk of cardiovascular complications. Materials and methods. The study included 40 patients (men and women) with grade I–III hypertension according to the ESC/ESH classification (2018). The mean age was 51.52 ± 9.43 years, and the average disease duration was 8.52 ± 6.64 years. Patients were divided into two groups: one received a fixed combination (lisinopril/amlodipine/rosuvastatin), and the other received a separate combination (perindopril/amlodipine and rosuvastatin). Treatment lasted for 3 months. Effectiveness was assessed using 24-hour blood pressure monitoring, applanation tonometry, echocardiography, ultrasound examination of brachiocephalic arteries, and laboratory analyses (lipid profile, glucose level, uric acid, and creatinine). Results. Both therapy regimens demonstrated high antihypertensive, organoprotective, and hypolipidemic effectiveness. However, patients receiving the fixed combination showed a more significant reduction in systolic and diastolic blood pressure, improved lipid profile, and decreased nighttime blood pressure variability. No adverse effects on metabolic profiles were observed. Conclusion. The fixed combination of drugs demonstrated superiority over the separate combination regimen, providing better blood pressure control and lipid profile improvement. These findings highlight the importance of selecting optimal therapy regimens for high cardiovascular risk patients and confirm the efficacy of fixed combinations in this patient group.
- Open Access
- 30 March 2021
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 106-117
METABOLOMIC APPROACHES IN STUDYING OF CARDIOVASCULAR DISEASES
Modern scientific approaches give clinicians an advantage in using additional tools and methods for assisting in clinical assessment and expanding their capabilities for classifying patients according to risk factors for cardiovascular complications. Biomarkers are a simple tool that allows to identify and classify people with different risk degree, quickly and accurately diagnose the condition of the disease, effectively predict and control treatment. Therefore, the identification and study of biomarkers is a serious and promising approach to understanding and treating cardiovascular diseases (CVD). Among a wide range of biomarkers, the genetic and metabolic markers is of high importance. Cardio-metabolomics is a new direction in cardiovascular science that allows researchers to study changes in metabolome and metabolic networks in diseases of the cardiovascular system in order to better understand their pathophysiological mechanism. Thus, the study of metabolome can provide important information about the pathogenesis of CVDs, as well as offer the possibility of identifying new CVD biomarkers.
- 30 March 2021
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 106-117
Open AccessMETABOLOMIC APPROACHES IN STUDYING OF CARDIOVASCULAR DISEASES
Modern scientific approaches give clinicians an advantage in using additional tools and methods for assisting in clinical assessment and expanding their capabilities for classifying patients according to risk factors for cardiovascular complications. Biomarkers are a simple tool that allows to identify and classify people with different risk degree, quickly and accurately diagnose the condition of the disease, effectively predict and control treatment. Therefore, the identification and study of biomarkers is a serious and promising approach to understanding and treating cardiovascular diseases (CVD). Among a wide range of biomarkers, the genetic and metabolic markers is of high importance. Cardio-metabolomics is a new direction in cardiovascular science that allows researchers to study changes in metabolome and metabolic networks in diseases of the cardiovascular system in order to better understand their pathophysiological mechanism. Thus, the study of metabolome can provide important information about the pathogenesis of CVDs, as well as offer the possibility of identifying new CVD biomarkers.